- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
AJMC in the Press, October 7, 2016
Highlights of our peer-reviewed research in the healthcare and mainstream press.
In Friday’s Morning eHealth daily report, POLITICO’s Darius Tahir discussed HIPAA in the age of cloud computing and mentioned a recent study in The American Journal of Managed Care (AJMC) that proposed expanding state prescription drug monitoring programs. The authors suggest expanding these programs to all prescription drugs, instead of just opiates.
Aledade’s report providing an inside look at the accountable care organizations (ACOs) the company has helped start continues to receive attention. As part of a Q&A with Aledade’s Farzad Mostashari, MD, Healthcare Informatics’ Rajiv Leventhal noted the report Mostashari co-wrote for AJMC and how the authors looked at ways CMS could prove the Medicare ACO programs.
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More
Bustling Gene Therapy Pipeline for Neuromuscular Diseases Brings Thorny Questions to the Clinic
March 18th 2025The rapid development of gene therapy options for treating neuromuscular diseases has created new therapeutic options but also logistical hurdles and a need for complex discussions between clinicians and families.
Read More
